Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Common Equity (2017 - 2025)

Historic Common Equity for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $120.1 million.

  • Aclaris Therapeutics' Common Equity fell 772.26% to $120.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.1 million, marking a year-over-year decrease of 772.26%. This contributed to the annual value of $155.6 million for FY2024, which is 103.39% down from last year.
  • As of Q3 2025, Aclaris Therapeutics' Common Equity stood at $120.1 million, which was down 772.26% from $131.7 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Common Equity registered a high of $235.8 million during Q2 2022, and its lowest value of $112.3 million during Q1 2021.
  • For the 5-year period, Aclaris Therapeutics' Common Equity averaged around $169.5 million, with its median value being $157.2 million (2023).
  • As far as peak fluctuations go, Aclaris Therapeutics' Common Equity skyrocketed by 43139.58% in 2021, and later plummeted by 2888.72% in 2023.
  • Aclaris Therapeutics' Common Equity (Quarter) stood at $197.3 million in 2021, then rose by 0.14% to $197.6 million in 2022, then fell by 20.46% to $157.2 million in 2023, then fell by 1.03% to $155.6 million in 2024, then decreased by 22.79% to $120.1 million in 2025.
  • Its Common Equity stands at $120.1 million for Q3 2025, versus $131.7 million for Q2 2025 and $144.1 million for Q1 2025.